logo
Share SHARE
FONT-SIZE Plus   Neg

Forest Labs, Pierre Fabre Report Results In Phase III Trial Of Levomilnacipran

Forest Laboratories, Inc. (FRX) and Pierre Fabre Medicament announced positive top-line results in a Phase III clinical trial of levomilnacipran, an investigational agent for the treatment of adults with major depressive disorder, or MDD.

Treatment with levomilnacipran significantly reduced depression symptoms in patients with MDD versus placebo, as early as week one and at each subsequent visit as measured by the Montgomery-Asberg Depression Rating Scale-Clinician Rated. Levomilnacipran was generally well-tolerated in this study. The premature discontinuation rates were 25 percent for levomilnacipran and 21 percent for placebo. The most common adverse events observed in the levomilnacipran group were nausea, dizziness and constipation.

Results from an additional placebo-controlled Phase III fixed-dose study are expected in Spring 2012.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
A group of consumers in New York and California have filed a lawsuit against Quaker Oats' owner PepsiCo Inc. alleging that the company has falsely advertised the oatmeal brand as "100 percent natural" despite having traces of glyphosate found in it. Lawsuit claims that glyphosate, a herbicide declared... Wal-Mart Stores Inc. (WMT) is bringing back its door-greeter program by mid-summer and station staffs at store entrances and exits as the retail giant looks to curb shoplifting. Previously, the retailer had reassigned employees serving as greeters to guide customers to checkouts and help them find... KFC has brought its "Finger Lickin' Good" tag line to life by creating KFC-flavored nail polishes. KFC Hong Kong has partnered with advertising agency Ogilvy & Mather to make "Original" and "Hot & Spicy" edible nail polishes. The flavors contain natural ingredients and are based on KFC's two popular...
comments powered by Disqus
Follow RTT